Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease

Autor:	K, Fellermann, M, Steffen, J, Stein, A, Raedler, J, Hämling, D, Ludwig, K, Loeschke, E F, Stange
Rok vydání:	2000
Předmět:	Adult Male Time Factors Crohn Disease Humans Prednisone Colitis Ulcerative Female Middle Aged Mycophenolic Acid Inflammatory Bowel Diseases Immunosuppressive Agents
Zdroj:	Alimentary pharmacologytherapeutics. 14(2)
ISSN:	0269-2813
Popis:	Mycophenolate mofetil (MMF) is a new immunosuppressant with pharmacodynamic properties comparable to azathioprine. Recent reports found MMF to be effective in inflammatory bowel disease (IBD).An open-label prospective and uncontrolled multicentre 6 month trial of MMF in combination with steroids was conducted in 24 chronic active IBD patients. A daily steroid demand of/= 10 mg prednisone in the preceding 2 months and a Crohn's disease activity index (CDAI)150, or moderate to severe activity according to Truelove, served as criteria for chronic activity. The treatment consisted of a steroid pulse and tapering protocol in combination with MMF 2 g/day. A prednisone dose of 5 mg/day was maintained during months 4-6. The primary end-point was induction and maintenance of remission.Only 10 of 24 patients had achieved remission after 3 months. All but one Crohn's disease patient had relapsed by the end of the study at 6 months. Depression and migraine necessitated drug withdrawal in two patients.In conclusion, MMF 2 g/day was unable to induce and maintain remission for a period of 6 months in 23 of 24 chronic active IBD patients. Further controlled investigations are required in view of recent conflicting reports.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::37f8b31f9a9792a34470d5248ec742f7 https://pubmed.ncbi.nlm.nih.gov/10651657 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.